Trial Profile
A PHASE 1 OPEN-LABEL, DOSE ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ENZALUTAMIDE (FORMERLY MDV3100) IN PATIENTS WITH INCURABLE BREAST CANCER
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Anastrozole; Exemestane; Fulvestrant
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Medivation; Pfizer
- 12 Feb 2018 Status changed from active, no longer recruiting to completed.
- 12 Jan 2018 Planned End Date changed from 1 Dec 2017 to 29 Jun 2018.
- 27 Oct 2017 Planned End Date changed from 31 Dec 2017 to 1 Dec 2017.